Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. stock TRY 45.49, price TRY 89.75, upside -49.3%, quality 63 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 29, 2026.
How to read this chart
46‑month range 19.16 TRY – 380.00 TRY · fair‑value band 24.07 TRY – 52.85 TRY · the 89.75 TRY price screens above the 45.49 TRY fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 29, 2026.
Follow Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. in your weekly email
Every Wednesday you see whether Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi manufactures and sells chemotherapy drug preparation kits and equipment in Turkey.
Show moreShow less
The company offers OncoCare Monolitik, an automated chemotherapy drug preparation device; OncoCare Plus, a chemotherapy drug guide; OncoWaste and M-Waste, a hazardous waste sealing system, chemotherapy drugs, cephalosporins, penicillins, infectious waste and toxic laboratory waste; OncoCare Set, a chemotherapy preparation and administration consumables; and Oncocare Infusion Pump.
It also provides Oncosem components, such as pinch clamps, roller clamps, 3/4 way connectors, vial adapters, drip chambers, hydrophobic caps, male and rotating luer locks, spikes, taxol filters, check valves, and covers. The company was incorporated in 2008 and is headquartered in Ankara, Turkey.
Stock analysis
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM) currently trades at 89.75 TRY, while our model-based Fair Value estimate is 45.49 TRY, 49.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 75.24 TRY per share, and 3 of the 22 models we run sit above the 89.75 TRY price.
Bear case: the Asset-Based group reads lowest at 7.84 TRY, and 19 of the 22 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 24.07 TRY (bear) to 52.85 TRY (bull), the price of 89.75 TRY sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. reported revenue of 709M TRY in FY2025 versus 128M TRY in FY2021, a compound +53.4%/yr. Reported net income was 50.4M TRY in FY2025, compounding −8.4%/yr from FY2021.
Key figures
Market cap 2.1B TRY (≈ $42.9M) Micro · P/E ratio 29.9 · P/S ratio 2.91 · EPS (TTM) 3.00 TRY · Net margin 9.6% · Return on equity 17.0% · Return on assets (EBIT) 15.3% · Operating margin 29.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 66 out of 100 (low confidence).
What moves the price
The share trades about 76% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −49%, ONCSM screens richer than that median.
Fair Value models
Bear24.07 TRYFair Value 45.49 TRYBull52.85 TRY
Price 89.75 TRY · Upside -49.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (2.49 TRY per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+44.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+47.6%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TRY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TRY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+2.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+2.2%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.29% → 23%
Growth Forecast
A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
Compare Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 328 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score63 · Above median
Fair Value upside−49.3% · Below median
Profitability
Return on equity (12 months)17.0% · Top 25%
Return on assets8.1% · Top 25%
Net margin (12 months)9.6% · Above median
Operating margin (12 months)29.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)2.3% · Below median
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)29.9× · Pricier than median
P/B5.26× · Priciest 25%
P/S (12 months)2.91× · Pricier than median
EV/EBITDA7.4× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 7
FUTURE (revenue growth)12· sector 34
PAST (return on equity)68· sector 16
HEALTH (low debt)99· sector 98
DIVIDEND (yield)0· sector 35
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. Fair Value". https://www.fairvalue-calculator.com/stock/ONCSM
Frequently asked questions
Is Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM) overvalued or undervalued?
As of Oct 29, 2026, our model estimates a fair value of 45.49 TRY versus a price of 89.75 TRY, about −49% upside (overvalued).
What is the fair value of ONCSM?
Our model-based fair value for Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. is 45.49 TRY (as of Oct 29, 2026), built from audited fundamentals. The current price: 89.75 TRY.
What is the quality score of ONCSM?
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM)?
Our model-based price target is the fair value of 45.49 TRY (as of Oct 29, 2026) from 22 valuation models. Cautious scenario 24.07 TRY, optimistic scenario 52.85 TRY. It is a calculation from audited fundamentals, not an analyst target.
What is the Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. stock forecast for 2026?
Our models put fair value at 45.49 TRY, about −49% upside versus a price of 89.75 TRY (overvalued). Cautious scenario 24.07 TRY, optimistic scenario 52.85 TRY. The calculation is refreshed regularly with new filings.
What is the revenue of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM)?
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. reported trailing-twelve-month revenue of about 735M TRY (latest available figure, as of Oct 29, 2026).
What growth is priced into Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM)?
For today's price to be fair in a discounted-cash-flow model, Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. would have to grow free cash flow by more than 80 % per year for five years (discount rate 13.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +47.6 % per year. As of Oct 29, 2026.
What discount rate (WACC) does the fair value of ONCSM use?
Our models discount Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. at 13.8 %: a base by market capitalisation (nano), damped by beta 0.88, country premium for Turkey. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. that is more than 80 % per year a year over ten years, using the same discount rate (13.8 %) and the same formula as our fair value.
How much growth has Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM) delivered so far?
Over the past 5 years revenue at Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. grew +47.6 % a year. The price currently implies more than 80 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM) growing?
The median revenue growth in the sector is +6.0 % a year. That is the yardstick for the growth priced into Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (more than 80 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM)?
The free-cash-flow yield on the price is 0.13 %: that much free cash flow Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. produces per unit of market value. When it exceeds the discount rate of our models (13.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. it is 45.49 TRY per share (as of Oct 29, 2026), against a price of 89.75 TRY. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. stock overvalued or undervalued in 2026?
As of Oct 29, 2026, ONCSM trades above its calculated fair value: price 89.75 TRY, fair value 45.49 TRY, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ONCSM?
No. The price is what the market pays today (89.75 TRY); the fair value is what the company's own numbers justify (45.49 TRY). For Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. the two are 44.26 TRY per share apart. That gap is exactly why we show both numbers side by side.
How much is Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. worth?
The market values Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. at about 2.1B TRY (market capitalisation, as of Oct 29, 2026). Per share that is 89.75 TRY; our models calculate a fair value of 45.49 TRY per share.
What do the bullish and bearish scenarios say about ONCSM?
Our models span a range for Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.: cautious scenario 24.07 TRY, base 45.49 TRY, optimistic 52.85 TRY per share (as of Oct 29, 2026, price 89.75 TRY). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ONCSM?
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. trades at a price-to-earnings ratio of 29.9 (as of Oct 29, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 45.49 TRY is built from several models across several years. Other multiples: P/B 5.3, P/S 2.9, EV/EBITDA 7.4.
How solid is the balance sheet of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM)?
Balance-sheet figures for Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (as of Oct 29, 2026): return on equity 17.0%, debt of 0.03 per unit of equity. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is ONCSM from its 52-week high?
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. trades at 89.75 TRY, about 76% below its 52-week high of 380.00 TRY and 13% above the low of 79.40 TRY (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of 45.49 TRY is for.
Which stocks are comparable to Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. stock attractive at the current price?
The data as of Oct 29, 2026: price 89.75 TRY, calculated fair value 45.49 TRY (−49%), Quality Score 63/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ONCSM calculated?
We run Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 45.49 TRY, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.1 % above its aggregate fair value. Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM)?
The closing price on Oct 28, 2026 was 89.75 TRY. Our model-based fair value is 45.49 TRY, about −49% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. right now?
The price sits above even our optimistic bull case (52.85 TRY). The favourable scenario is already priced in. Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (24.07 TRY to 52.85 TRY) leaves room in how you read the outcome.
Key figures of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.
How large is the market capitalisation of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM)?
The market capitalisation of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. is 2.1B TRY (≈ $42.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM)?
The price-to-sales ratio of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. is 2.91 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM)?
Earnings per share at Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. are 3.00 TRY (price ÷ EPS = P/E 29.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM)?
The net margin of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. is 9.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM)?
The return on equity (ROE) of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. is 17.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM)?
On an EBIT basis the return on assets of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. is 15.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM)?
The operating margin of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. is 29.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM)?
Revenue at Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. is growing +2.3% versus a year earlier (3y avg +34.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM)?
Earnings per share at Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. are growing +118% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM) carry?
The net debt of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. is 41.4M TRY (fiscal year 2025, ≈ 15.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. in the live analysis
One click puts Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Some data
Oct 29, 2026